These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 27769596)

  • 21. [The importance of the second generation adjuvanted systems in "new" vaccines].
    Beran J
    Klin Mikrobiol Infekc Lek; 2008 Feb; 14(1):5-12. PubMed ID: 18327735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Adjuvants and Immunomodulators for Veterinary Vaccines.
    Heegaard PM; Fang Y; Jungersen G
    Methods Mol Biol; 2016; 1349():63-82. PubMed ID: 26458830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current progress of immunoinformatics approach harnessed for cellular- and antibody-dependent vaccine design.
    Kazi A; Chuah C; Majeed ABA; Leow CH; Lim BH; Leow CY
    Pathog Glob Health; 2018 May; 112(3):123-131. PubMed ID: 29528265
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vaccine candidate discovery for the next generation of malaria vaccines.
    Tuju J; Kamuyu G; Murungi LM; Osier FHA
    Immunology; 2017 Oct; 152(2):195-206. PubMed ID: 28646586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computational tools for epitope vaccine design and evaluation.
    He L; Zhu J
    Curr Opin Virol; 2015 Apr; 11():103-12. PubMed ID: 25837467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular signatures of vaccine adjuvants.
    Olafsdottir T; Lindqvist M; Harandi AM
    Vaccine; 2015 Sep; 33(40):5302-7. PubMed ID: 25989447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of immunomodulators on the response induced by vaccines against autoimmune diseases.
    Marciani DJ
    Autoimmunity; 2017 Nov; 50(7):393-402. PubMed ID: 28906131
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity.
    Martins KAO; Cooper CL; Stronsky SM; Norris SLW; Kwilas SA; Steffens JT; Benko JG; van Tongeren SA; Bavari S
    EBioMedicine; 2016 Jan; 3():67-78. PubMed ID: 26870818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials.
    Nardin E; Zavala F; Nussenzweig V; Nussenzweig RS
    Parassitologia; 1999 Sep; 41(1-3):397-402. PubMed ID: 10697892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational design of conjugate vaccines.
    Dintzis RZ
    Pediatr Res; 1992 Oct; 32(4):376-85. PubMed ID: 1437386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant and epitope-based vaccines on the road to the market and implications for vaccine design and production.
    Oyarzún P; Kobe B
    Hum Vaccin Immunother; 2016 Mar; 12(3):763-7. PubMed ID: 26430814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Canine Leishmania vaccines: still a long way to go.
    Gradoni L
    Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR; Kiyono H
    Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal Vaccine Development Based on Liposome Technology.
    Bernasconi V; Norling K; Bally M; Höök F; Lycke NY
    J Immunol Res; 2016; 2016():5482087. PubMed ID: 28127567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systems integration of innate and adaptive immunity.
    Zak DE; Aderem A
    Vaccine; 2015 Sep; 33(40):5241-8. PubMed ID: 26102534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modern Vaccine Adjuvant/Formulation--Session 9: Adjuvants.
    Dalençon F
    Hum Vaccin Immunother; 2013 Sep; 9(9):2013-4. PubMed ID: 23938771
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glycans as Vaccine Antigens and Adjuvants: Immunological Considerations.
    Zimmermann S; Lepenies B
    Methods Mol Biol; 2015; 1331():11-26. PubMed ID: 26169732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer vaccine adjuvants--recent clinical progress and future perspectives.
    Banday AH; Jeelani S; Hruby VJ
    Immunopharmacol Immunotoxicol; 2015 Feb; 37(1):1-11. PubMed ID: 25318595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.